Monday, April 06, 2015 3:39:34 PM
Before we go into MabVax, it is helpful to understand the recent movement of Opko's share price in light of its past investment moves. While Opko has its own pipeline candidates, most notably Rayaldee which has completed phase 3 and is on the verge of applying for an NDA, it is actually Opko's previous investments that have catalyzed its most recent 75% upsurge since December.
On December 15, Opko announced a $570M licensing deal with Pfizer (NYSE:PFE) for its long-acting human growth hormone hGH-CTP, including a $295M down payment from the Big Pharma giant, and an additional $275M in milestone payments. Opko, however, did not develop hGH-CTP on its own. It acquired it when it acquired Prolor Biotech two years ago for $480M. Since the announcement of the deal with Pfizer, Opko's market cap has skyrocketed over 75%, or $2.8B. While it could be argued that Rayaldee's phase 3 success accounts for some of this gain, Rayaldee succeeded in its pivotal phase 3 trial back in September. This latest 75% move didn't begin until after the Pfizer announcement.
So in the end, for a $480M deal, both Opko and Prolor shareholders have been rewarded with a $2.8B equity gain.
Prolor, however, is not the only investment that has succeeded for Opko and Frost. Neovasc (NASDAQ:NVCN), a trial-stage cardiovascular device company focusing on devices for angina and mitral regurgitation, has surged 765% since Opko first took a 6% position in August 2011. Dr. Frost owned 36% of the company before Opko came in. Neovasc has raised $110M in equity just over the last 12 months, so investors are eagerly following Opko and Frost's lead.
Opko also owns 8% of biotech firm Cocrystal Pharma (OTCQB:COCP), with Frost himself owning 14.3%. Cocrystal has skyrocketed 200% since February, and is Opko's second largest holding in its investment portfolio.
Even more recently, Opko took one of its private equity investments public through a merger with Levon Resources (OTCQX: LVNVF). Israeli biotech firm SciVac, which markets a 3rd generation hepatitis B vaccine, was 45% owned by Opko, now 31% in light of the merger. While the deal is still fresh and trends are not definitive yet, Levon has nevertheless moved up 40% since announcement of the deal.
Which brings us to MabVax. This is a company that already has licensing deals with big names in the oncology space like Sloan Kettering and Juno Therapeutics (NASDAQ:JUNO), which itself has jumped 63% since its December IPO. MabVax essentially filters through cancer antibody candidates produced naturally by patients administered cancer vaccines at Sloan Kettering, bringing the most promising antibodies through clinical development. Juno has a deal with MabVax allowing it to use MabVax's candidates as a targeting mechanism for its own pipeline, while at the same time MabVax is developing its lead antibody HuMab 5B1 as both an imaging agent for pancreatic cancer and as a therapeutic.
Mabvax, which only had about $3.5M in cash as of Q3 2014 with a much higher annual burn rate, was in need of an institutional investor in order to move forward and it got one. MabVax's market cap is still only $18M, so a $12M investment is quite substantial in light of the company's size. Will Opko eventually go the whole way with MabVax like it did with Prolor? Hard to say, but evidence that Opko is at least considering it lay in the fact that Steven Rubin, Opko's Executive Vice President, will be getting a seat on the MabVax advisory board.
Considering Opko's success of late as a biotech holding company, the relatively small sum - for now - that Frost and Opko are sinking into MabVax may prove to be just the beginning.
CONTACT:
Company: BiotechStocks.com
Contact Name: Adam Heimann
Contact Email: adam@egmfirm.com
SOURCE: BiotechStocks.com
Recent OPK News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:29:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:07:44 PM
- OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 09:02:37 PM
- AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • GlobeNewswire Inc. • 03/05/2024 01:52:22 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 09:05:23 PM
- NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st • PR Newswire (US) • 02/28/2024 02:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:07:54 PM
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/16/2024 09:53:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:07:24 PM
- NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China • PR Newswire (US) • 02/05/2024 01:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 08:30:14 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:00:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:09:07 PM
- OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes • GlobeNewswire Inc. • 01/09/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 02:10:34 PM
- OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM